VR Logo

Travere Therapeutics Inc. (TVTX) download report


Healthcare | Biotechnology & Pharma Research

Travere Therapeutics Inc. (TVTX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases.

IPO Date: 08-Nov-2012

Pres, CEO & Director: Dr. Eric M. Dube Ph.D.

Chief Financial Officer: Ms. Laura M. Clague CPA, CPA

Listing: NASDAQ: TVTX

Country: United States

Headquarters: San Diego, CA

Website: https://www.travere.com

Key Facts

Market cap: $1,567.53 Mln

Revenue (TTM): $228.57 Mln

Earnings (TTM): $-202.20 Mln

Cash: $603.39 Mln

Total Debt: $408.79 Mln

Insider's Holding: 1.44%

Liquidity: Low

52 Week range: $12.75 - 31.65

Shares outstanding: 63,514,200

9 Years Aggregate:

  • CFO: $-201.08 Mln
  • EBITDA: $-691.64 Mln
  • Net Profit: $-881.37 Mln

Stock Performance

Time Period Travere Therapeutics (TVTX) S&P BSE Sensex S&P Small-Cap 600
YTD-19.17-9.18-18.78
1 month4.54-4.78-8.00
3 months-2.64-9.66-13.65
1 Year71.970.81-17.19
3 Years7.6910.336.10
5 Years5.2911.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Travere Therapeutics (TVTX) S&P Small-Cap 600 S&P BSE Sensex
202113.8925.2721.99
202091.949.5715.75
2019-37.2520.8614.38
20187.36-9.705.87
201711.3011.7327.91
2016-1.8724.741.95
201557.60-3.36-5.03